Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

5/11/23 9:25:42 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Medical/Dental Instruments

Health Care

Get the next $ESPR alert in real time by email

The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Sensus Healthcare

The Trade: Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Samuel O'Rear acquired a total 20,000 shares an average price of $2.99. To acquire these shares, it cost around $59.85 thousand. The company’s President and General Counsel also bought the company’s shares.
What’s Happening: Sensus Healthcare reported worse-than-expected Q1 EPS and sales results.
What Sensus Healthcare Does: Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system.

Esperion Therapeutics

TCR2 Therapeutics

Check This Out: Investor Sentiment Declines Slightly Following Inflation Data

Don’t forget to check out our premarket coverage here

Get the next $ESPR alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ESPR
$SRTS
$TCRR

Company	Date	Price Target	Rating	Analyst
Sensus Healthcare Inc. $SRTS	3/6/2026	$7.50	Buy	Alliance Global Partners
Esperion Therapeutics Inc. $ESPR	11/25/2025	$9.00	Overweight	Piper Sandler
Sensus Healthcare Inc. $SRTS	1/31/2025	$18.00	Buy	Lake Street
Esperion Therapeutics Inc. $ESPR	12/18/2024	$4.00	Neutral	Goldman
Esperion Therapeutics Inc. $ESPR	12/17/2024	$8.00	Overweight	Cantor Fitzgerald
Sensus Healthcare Inc. $SRTS	11/15/2024	$12.00 → $14.00	Buy	Maxim Group
Esperion Therapeutics Inc. $ESPR	6/20/2024	$2.50	Neutral → Underperform	BofA Securities
Esperion Therapeutics Inc. $ESPR	1/3/2024		Buy → Neutral	BofA Securities

More analyst ratings

$ESPR
$SRTS
$TCRR
Press Releases

Fastest customizable press release news feed in the world

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

3/10/26 6:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

First-in-class, once-daily oral non-statin therapy now available by prescription across CanadaAddresses a significant unmet need for over half a million Canadians who can not get to their LDL-C goal on statin-based therapy or who are statin intolerantSupported by the landmark CLEAR Outcomes trial demonstrating reduction in major adverse cardiovascular events in nearly 14,000 patientsTORONTO, March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now ava

3/5/26 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

3/3/26 6:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Investment Managers

Finance

$ESPR
$SRTS
$TCRR
Leadership Updates

Live Leadership Updates

Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi

1/7/26 8:30:00 AM ET

Medical/Dental Instruments

Health Care

Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

11/12/25 8:00:00 AM ET

Medical/Dental Instruments

Health Care

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

11/4/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care